We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 852% below its sector, cheaper than its peers on earnings.
Selvita S.A., a contract research organization (CRO), provides its services across Poland, throughout Europe, in the United States, and to global clients. The company is structured around two main divisions: its core Contract Research Organization (CRO) offerings and Bioinformatics. Within its drug discovery portfolio, Selvita delivers a comprehensive suite of services including assay development and screening, expertise in medicinal and synthetic chemistry, advanced computer-aided drug design leveraging artificial intelligence, structural biology, in vitro and in vivo pharmacology studies, ADME/DMPK assessments, and general analytical testing. Furthermore, Selvita extends its capabilities to pharmaceutical services, encompassing drug testing and bioanalytical analysis. These services cover development and optimization processes, validation and transfer, stability studies, rigorous quality control, and assistance with regulatory compliance. The organization also engages in diverse research and development activities, such as process research, bespoke laboratory-scale synthesis of New Chemical Entities (NCEs), industrial chemistry solutions, and the creation of isotopically labeled compounds. Support for the agrochemical industry is also part of their R&D offerings. Moreover, Selvita delivers specialized bio-data science and sophisticated software solutions tailored for data-centric organizations within the life science and healthcare sectors. Established in 2007, Selvita S.A. maintains its headquarters in Krakow, Poland.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save SLV.WA and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
